{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:45:52Z","timestamp":1776235552813,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pemetrexed is a folate-pathway-targeting antineoplastic agent widely used in non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. We used the US Food and Drug Administration Adverse Event Reporting System (FAERS) to characterize pemetrexed-associated adverse events to inform clinical safety monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pemetrexed-related reports were retrieved from the FAERS database from first quarter of 2004 through the fourth quarter of 2024. All reports were coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. We performed descriptive analyses and disproportionality analyses using reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayes geometric mean (EBGM), and Bayesian confidence propagation neural network (BCPNN; information component [IC]) to identify safety signals. Statistical significance was defined as ROR &amp;gt;1 with the lower 95% confidence interval (CI) &amp;gt;1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 27,098 pemetrexed-associated reports in the FAERS database (2004\u20132024), in which pemetrexed was designated as the primary suspect drug. Signal detection based on these reports identified 653 significant signals of disproportionate reporting (SDR) spanning 27 System Organ Classes (SOCs). The strongest signals occurred in Blood and Lymphatic Disorders (ROR = 7.31, 95% CI = 7.16\u20137.47) and Endocrine disorders (ROR = 4.09, 95% CI = 3.83\u20134.37), the latter representing unlabeled findings. In addition, we detected previously unlisted AEs, including colitis, oral lesions, immune-mediated pancreatitis, pulmonary toxicity, lung consolidation and tubulointerstitial nephritis. Sex stratification revealed male predominance in respiratory toxicity vs. female predisposition to renal injury. A bimodal time-to-onset distribution was observed: 52.57% of AEs occurred within 0\u201330 days post-treatment, with a secondary peak (6.63%) at 181\u2013360 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This large pharmacovigilance study identifies signals of disproportionate reporting (SDRs) consistent with pemetrexed's established toxicities (e.g., myelosuppression, nephrotoxicity) and detects additional unlabeled safety signals, particularly immune-mediated endocrine, renal, and dermatologic manifestations. The bimodal onset pattern of these SDRs highlights clinically relevant monitoring windows, and observed sex- and age-related differences in SDR reporting suggest a need for individualized risk mitigation. These findings underscore the importance of vigilant surveillance for potential immune-mediated toxicities and adherence to vitamin supplementation protocols to manage hematologic risk. Prospective studies are needed to validate these reporting associations and clarify potential causality for these novel signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1750861","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:44:33Z","timestamp":1776231873000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events profiles of pemetrexed: a Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.3389","volume":"13","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[{"name":"The Sixth People's Hospital of Huizhou","place":["Huizhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JianHang","family":"Su","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen Memorial Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuliang","family":"Huang","sequence":"additional","affiliation":[{"name":"The Sixth People's Hospital of Huizhou","place":["Huizhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukun","family":"Yang","sequence":"additional","affiliation":[{"name":"The Sixth People's Hospital of Huizhou","place":["Huizhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanqing","family":"Xu","sequence":"additional","affiliation":[{"name":"The Sixth People's Hospital of Huizhou","place":["Huizhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","article-title":"FDA drug approval summaries: pemetrexed (alimta)","volume":"9","author":"Hazarika","year":"2004","journal-title":"Oncologist."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.clinthera.2005.09.010","article-title":"Pemetrexed: a multitargeted antifolate","volume":"27","author":"Rollins","year":"2005","journal-title":"Clin Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"113456","DOI":"10.1016\/j.ejca.2023.113456","article-title":"Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): a randomized, open-label, multicenter, phase II trial","volume":"197","author":"Lee","year":"2024","journal-title":"Eur J Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cncr.10755","article-title":"The pemetrexed\/gemcitabine combination in pancreatic cancer","volume":"95","author":"Kindler","year":"2002","journal-title":"Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1586\/era.09.141","article-title":"Emerging role of pemetrexed in ovarian cancer","volume":"9","author":"Tomao","year":"2009","journal-title":"Expert Rev Anticancer Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1136\/ijgc-00009577-200605000-00034","article-title":"Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial","volume":"16","author":"Goedhals","year":"2006","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.21037\/atm-20-1095","article-title":"Analysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer","volume":"8","author":"Yu","year":"2020","journal-title":"Ann Transl Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","article-title":"Mechanisms, management and prevention of pemetrexed-related toxicity","volume":"44","author":"de Rouw","year":"2021","journal-title":"Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: an overview","volume":"40","author":"Beninger","year":"2018","journal-title":"Clin Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.21037\/tlcr.2019.10.14","article-title":"Mechanisms of resistance to pemetrexed in non-small cell lung cancer","volume":"8","author":"Liang","year":"2019","journal-title":"Transl Lung Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1200\/jco.2004.22.90140.7201","article-title":"Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM)","volume":"22","author":"Karthaus","year":"2004","journal-title":"J Clin Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","article-title":"Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors","volume":"6","author":"Hanauske","year":"2001","journal-title":"Oncologist."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/annonc\/mdf115","article-title":"Phase II trial of pemetrexed disodium (ALIMTA\u00ae, LY231514) in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer","volume":"13","author":"Clarke","year":"2002","journal-title":"Ann Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non\u2013small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/14737140.4.4.511","article-title":"Pemetrexed: a novel antifolate agent enters clinical practice","volume":"4","author":"Kut","year":"2004","journal-title":"Expert Rev Anticancer Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1634\/theoncologist.2014-0221","article-title":"A prospective study of shortened vitamin supplementation prior to cisplatin\u2013pemetrexed therapy for non-small cell lung cancer","volume":"19","author":"Takagi","year":"2014","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cllc.2018.05.017","article-title":"Safety of same-day vitamin B12 supplementation in patients receiving pemetrexed for the treatment of non-small-cell lung cancer or pleural mesothelioma: a retrospective analysis","volume":"19","author":"Schlei","year":"2018","journal-title":"Clin Lung Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/cncr.32028","article-title":"Timing of folic acid\/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: the PEMVITASTART randomized trial","volume":"125","author":"Singh","year":"2019","journal-title":"Cancer."},{"key":"B21","first-page":"53","article-title":"Widespread use of pemetrexed in oncology: has it turned it into a new drug?","volume":"3","author":"Cidon","year":"2014","journal-title":"Chin Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.4081\/cp.2011.e106","article-title":"Pemetrexed induced pneumonitis","volume":"1","author":"Dhakal","year":"2011","journal-title":"Clin Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e5514","DOI":"10.7759\/cureus.5514","article-title":"Pemetrexed induced life-threatening anaphylaxis","volume":"11","author":"Rajasurya","year":"2019","journal-title":"Cureus."},{"key":"B24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","article-title":"Cumulative pemetrexed dose increases the risk of nephrotoxicity","volume":"146","author":"De Rouw","year":"2020","journal-title":"Lung Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2146\/ajhp160181","article-title":"Mild hyperamylasemia and early-phase drug-induced pancreatitis","volume":"73","author":"Cataltepe","year":"2016","journal-title":"Am J Health Syst Pharm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"14121","DOI":"10.3390\/ijms232214121","article-title":"Myocardial protection and current cancer therapy: two opposite targets with inevitable cost","volume":"23","author":"Efentakis","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3892\/mco.2014.452","article-title":"Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed","volume":"3","author":"Sakamori","year":"2015","journal-title":"Mol Clin Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1750861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:44:34Z","timestamp":1776231874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1750861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":27,"alternative-id":["10.3389\/fmed.2026.1750861"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1750861","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1750861"}}